Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-142P** refers to a *pseudogene* of U6 small nuclear RNA (snRNA). The canonical U6 snRNA is a highly conserved, abundant noncoding RNA component of the spliceosome, playing a critical role in pre-mRNA splicing by assembling at the heart of the spliceosome’s active site and coordinating the chemistry of intron removal[1][2]. However, pseudogenes such as RNU6-142P are nonfunctional genomic DNA sequences that resemble functional snRNA genes but are generally not transcribed or, if transcribed, do not participate in the canonical spliceosomal activity[3]. These pseudogenes may arise through genome duplication or retrotransposition events over evolutionary time, and while they sometimes play regulatory regulatory roles, most have no known biological function[3]. RNU6-142P is therefore not considered a therapeutic target, a receptor, or an enzyme.\n\n**Key context:**\n- The **U6 snRNA** is essential for splicing, but this entry refers specifically to a *pseudogene*, meaning it is a nonfunctional copy[1][2][3].\n- There is no evidence that **RNU6-142P** acts as a receptor, enzyme, transporter, or any other classical drug target class.\n- The molecule is generally not part of any disease mechanism, is not a biomarker, and is not targeted by any drugs.\n- Pseudogenes like RNU6-142P may serve as genetic markers in some genomic studies but do not have established roles in human biology or therapeutics[3].\n\nIf you require information on the active, functional U6 snRNA (not a pseudogene), please clarify.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 142, pseudogene (RNU6-142P).